Lexeo Therapeutics

We are proud to share positive interim data of LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy. Across two clinical trials – the SUNRISE-FA Phase 1/2 trial sponsored by Lexeo and a Phase 1A Weill Cornell Medicine investigator-initiated trial – LX2006 was well tolerated with no treatment-related serious adverse events, and clinically meaningful improvements in cardiac biomarkers were observed with increasing improvement over time.   Read more here: https://lnkd.in/e2QD2YKA

Lexeo will present interim clinical data on LX2006, an AAVrh10.hFXN gene therapy candidate for the treatment of Friedreich ataxia (FA) cardiomyopathy, on Monday July 15. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo’s ongoing SUNRISE-FA Phase 1/2 clinical trial and the ongoing Weill Cornell Medicine investigator-initiated trial, as well as an overview of program next steps. https://lnkd.in/e77gXJDN

Happy Independence Day!   We wish everyone a safe, celebratory, and fun holiday to mark our nation’s independence. #OneLexeo

We're excited to feature our VP of clinical development, cardiology, Franca A., MD, PhD in our latest Employee Spotlight! Franca is a key member of our team, bringing passion and dedication to her work in cardiology. Her commitment to innovation and patient care exemplifies the values we hold at Lexeo. Check out the below to learn more about Franca. #OneLexeo 

Arrhythmogenic cardiomyopathy (ACM), a genetic heart disease, is characterized by changes to the heart muscle, which affect its electrical activity. This condition leads to scarring, heart dysfunction and, in severe cases, sudden death. In the US, an estimated 130,000 individuals are affected, and more than half having a genetic cause, primarily associated with mutations in the PKP2 gene.     At Lexeo, we are developing a number of disease-modifying gene therapy candidates to treat cardiovascular diseases with significant unmet need. Our investigational AAV-based gene therapy LX2020, is being evaluated to deliver a fully functional PKP2 gene to heart muscle for the treatment of PKP2-ACM.    Learn more about our AAV-based gene therapy candidate, LX2020:   https://lnkd.in/gNWDX9aQ  

Congratulations to Sarepta Therapeutics on receiving FDA's full approval of their gene therapy for ambulatory Duchenne muscular dystrophy (DMD) in patients four years or older. This is a critical milestone for patients with DMD and their loved ones, and it underscores the importance of accelerated approval as a potential path to get more cell and gene therapies to patients more quickly, especially when unmet needs are high and current treatments do not fully address them. We are excited to see this progress for patients, and within the field, as we work to realize the full potential of genetic medicines.

Today, all of us at Lexeo join the nation in commemorating #Juneteenth. We are dedicated to advancing equity for all, and fostering a future where every voice is heard, and every individual is valued.  Do you know the story of #Juneteenth? Learn more and join in the celebration with Smithsonian's National Museum of African American History and Culture:   nmaahc.si.edu/Juneteenth 

Happy #PrideMonth!    Lexeo proudly stands in solidarity with the #LGBTQ+ community. We are committed to cultivating an inclusive work environment for all. #OneLexeo #Pride 

June marks Alzheimer’s & Brain Awareness Month. Did you know that the risk of developing Alzheimer’s disease may be influenced by your genes? People who are APOE4 homozygous, meaning they have two copies of a gene variant called APOE4, are approximately 15 times more likely to develop Alzheimer’s.     Lexeo is developing CNS-focused gene therapies to address the underlying genetic cause of APOE4-associated Alzheimer’s disease.    Learn more about our programs here:  https://lnkd.in/g2BGvuSM     #ENDALZ #ALZScience 

Our leadership team truly valued the opportunity to connect professionally and personally during a recent offsite.    We focused on how we can potentially bring #genetherapy candidates to patients more quickly and discussed how Lexeo values can bolster our day-to-day culture and organizational goals.    We also had time for some fun! Check out some of our photos! #OneLexeo